During normal haematopoiesis, cell development and differentiation programs are accomplished by switching 'on' and 'off ' 
Introduction
Haematopoiesis is a continuous and stepwise controlled process in which the pluripotent haematopoietic stem cells (HSCs) undergo differentiation to produce all mature blood cell lineages, which comprise the effector cells of both innate and acquired immunity. These cells fulfil specific roles in the host defence against invading pathogens and in the maintenance of homeostasis [1] . The [4] . [5] . Based on bacterial gene regulation models, it has been proposed that protein interactions between the individual enhancer-bound factors serve to promote cooperative assembly on the DNA [6] . Recent observations, however, demonstrate that major functions of typical transcription factors do not require DNA binding, suggesting that due to their protein interaction potential, transcription factors carry information beyond the stabilization of DNA contacts [7] . [8, 9] whereas its knockout leads to a profound deficit in the development of neutrophils/monocytes and B cells, followed by an impairment in T-and natural killer (NK) cells but megakaryocyte/ erythroid (Meg/E) development remains intact [10, 11] . The overexpression of PU.1 in erythroid cells blocks differentiation and promotes erythroleukemic transformation, whereas its reduced expression in mice has been associated with the development of myeloid leukaemia [12, 13] [62] .
Rather than being controlled by a single master regulator, lineage-specific gene expression depends on the combination of factors that bind in overlapping functional domains. Gene transcription requires the assembly of RNA polymerase II with a multiprotein pre-initiation complex at specific DNA sequences including the TATA box in a promoter. Interactions of general transcription factors with basal promoter elements are generally essential for basal transcription but not sufficient to modulate its rate. Therefore, the activation or repression of gene transcription takes place when several transcription factors bind to their cognate sequences on the lineage-specific promoters and stimulate or inhibit transcription through protein-protein interactions with the basal transcription machinery

In addition, transcription factors interact with other trans-regulatory proteins such as co-activators, co-repressors, chromatin remodelling factors and/or bridging factors to form gene regulatory complexes. For instance, in some cases interaction between transcription factors is required to modify chromatin in such a way that a previously silent gene may become accessible to the activation machinery. Once the chromatin is favourably restructured and the gene 'prepared' for expression, the transcription machinery needs to be recruited. Among various transcription factors, the ETS factors are known to play a significant role in the regulation (activation or repression) of genes associated with pathogen and tumour defence. Especially, transcription factor PU.1 appears to have the greatest impact on immunity, primarily through its control of immune cell (myeloid and B-lymphoid) development. The deregulated PU.1 function severely impairs haematopoietic development. Its complete disruption causes embryonic and/or newborn lethality in mice
PU.1 gene regulation
PU.1-interacting proteins
Despite the importance of PU.1, it is not a lone determinant of immune cell development. A variety of proteins have been identified as interaction partners of PU.1. These proteins include other transcription factors, non-DNA binding cofactors, chromatinremodelling factors and proteins involved in cell cycle regulation. The activation of gene expression mediated by transcription factor PU.1 is generally associated with synergistic interactions with other transcriptional regulators. For example, PU.1 has been shown to cooperate with NF-IL6␤ (C/EBP-␦) [43], c-Myb and C/EBP-␣ [63], c-Jun and c-Fos [40].
However, the regulation of transcription factor activity is not only restricted to synergistic combinatorial associations but negative interactions between transcription factors also play a critical role in the control of haematopoiesis. It has been presumed that transcription factors play a key role in the induction of differentiation events and the process of haematopoietic lineage commitment through antagonistic regulation of alternate lineage-specific factors [64] . For example, a negative cross-talk between PU.1 and GATA-1 plays a significant role in erythro-myeloid lineage commitment [65] . A list of PU.1-interacting proteins has been shown in Table 1 . [66] . [67] . Homozygous [67, 68] . (Fig. 3) [76] (Fig. 4) (Fig. 4) [78] .
Both activators and repressors may function by interacting with components of basal transcriptional apparatus, leading to modulation of transcription initiation. The function of an activator may be to recruit the basal transcriptional machinery to a promoter or to induce conformational changes in the complex either at the pre-initiation or elongation steps. However, the role of repressors is not well defined. They may act by specifically interfering, through their repressor domain, with the assembly of the transcriptional machinery (active repression), or they may mediate repression by quenching activators or co-activators (passive repression). Both activators and repressors require co-activator and co-repressors, respectively. These co-factors may function as bridging molecules between the transcription factors and the basal transcriptional machinery, facilitating or inhibiting recruitment to the promoter
NF-IL6␤ (C/EBP-␦)
NF-IL6␤ is a leucine zipper transcription factor that belongs to the family of C/EBP proteins. It is a potent transactivator protein implicated in inflammatory responses
C-Jun
CBP binds and stimulates the activity of erythroid-specific transcription factor GATA-1 by acetylating its two highly conserved lysine-rich motifs near each of the two zinc fingers [79] [84, 85] , erythropoietin receptor [86] , erythroid Kruppel-like factor [87] , ␣-spectrin [88] , platelet factor 4 [89] , glycoprotein IIb [90] and so on. GATA-1 also plays an essential role in eosinophil development. GATA-1 null mouse embryos die from severe anaemia between embryonic day E10.5 and E11.5 [91] . [95] .
GATA-1
GATA-1 is a key erythroid transcription factor required for the development of normal erythroid and megakaryocytic lineages in which it regulates the expression of many specific genes, such as, ␣-and ␤-globin genes
Antagonism between GATA-1 and PU.1 Several lines of evidence suggest that GATA-1 and PU.1 functionally antagonize each other through direct physical interaction via the DNA-binding domains of both proteins [41, 42, 65]. But the mechanisms by which these transcription factors antagonize each other are quite distinct. Zhang et al. demonstrated that the N-terminal TAD of PU.1 physically interacts with the conserved C-terminal zinc finger of GATA-1 and blocks its DNA-binding ability in vitro and in vivo, thereby repressing GATA-1-mediated transcription of its target genes [83] (Fig. 5). Both the DNA binding and transactivation domains of PU.1 are required for inhibition of GATA-1-dependent transcription. In Xenopus embryos, ectopic expression of PU.1 blocks erythropoiesis during normal development. Introduction of exogenous GATA-1 can trigger Xenopus embryos to resume differentiation and undergo terminal cell division in order to lose their tumorigenicity [41]. Thus, the stoichiometry of these two mutually antagonistic transcription factors is important not only during normal erythroid development but also during leukemogenesis [92]. On the contrary, GATA-1 represses the transcriptional activity of PU.1 by blocking the binding of its co-activator c-Jun to the ␤3/␤4 region in its DNA-binding domain [40, 65] (Fig. 5). The carboxyterminal zinc finger of GATA-1 interacts with the ␤3/␤4 region of PU.1, and disrupts the PU.1/c-Jun interaction in a competitive manner, thereby blocking c-Jun from co-activating PU.1 [41]. In many acute leukaemias and some lymphomas, aberrant differentiation is a major feature of the malignant phenotype that often results from a single genetic alteration and hence provides a site-specific target for therapy. For example, deregulation of PU.1 in erythroid precursors can cause erythroleukaemias in mice. Differentiation induction of haematological malignant cells as well as normal HSC differentiation is mediated by a stochiometric ratio of transcription factors GATA-1 and PU.1 [41], which broadly determine lineage and cooperate with more specific transcription factors such as RAR receptor and CEBP family members [59, 93, 94]. Erythropoietin-induced erythroid differentiation of leukemic cells is associated with GATA-1 induction and down-regulation of © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
The synergistic effect of PU.1 on GATA-1-mediated transactivation is mediated by a conformational change in GATA-1 when it binds through both of its C-and N-terminal zinc fingers to the two canonical non-overlapping tandem GATA-binding sites present in the MBP-P2 promoter. Involvement of the N-terminal zinc finger by binding to the other GATA site in the MBP-P2 promoter might trigger a conformational change leading to decreased DNA binding activity of the C-terminal zinc finger and a decrease in transac-
tivating activity for the ␤-globin silencer [96] [97] [98] [99] . [95] . [24, 101] . C/EBP-␣-null mice lack the entire granulocyte lineage but develop normal monocytes [102] .
Interestingly, C/EBP family members C/EBP-and C/EBP-␤, were found to antagonize both GATA-1 transactivation and GATA-1/PU.1 synergistic activation of the eosinophil MBP-P2 promoter, as well as PU.1-mediated transactivation of PU.1 target genes/promoters such as the M-CSFR, suggesting a potent repressor function for this isoform in myeloid development
C/EBP-␣ C/EBP-␣ (CAAT/EBP), a bZip transcription factor, regulates not only a variety of hepatocyte and adipocyte genes, but several myeloid-specific genes as well [100]. For example, it regulates M-CSF receptor, G-CSF receptor and GM-CSF receptor ␣ promoters. C/EBP-␣ expression is prominent in immature myeloid cells
Combinations of inhibition and autoregulation involving PU.1 and C/EBP-␣ have been hypothesized to mediate the decision of myeloid progenitors to differentiate into either granulocytes or monocytes [103, 104] . The haematopoietic progenitors require PU. 1 [106, 107] .
to initiate monocyte differentiation and C/EBP-␣ to initiate granulopoiesis. Laslo et al. have shown that nonlinear positive feedback regulates differentiation of CMPs into macrophages or neutrophils [105]. Earlier it was suggested that the relative difference in expression of the transcription factors PU.1 and C/EBP-␣ regulates the differentiation of CMPs [103]. They found that macrophage differentiation is favoured when the level of PU.1 is higher than that of C/EBP-␣, whereas neutrophil differentiation is favoured when the level of C/EBP-␣ is higher than that of PU.1. Thus a mutual corepression was thought to exist between PU.1 and C/EBP-␣ that drives CMPs towards one fate or the other. Each factor has been shown to synergize on various promoters, including M-CSF receptor promoter and neutrophil elastase (NE) promoter [24, 63]. Each is expressed in a bipotential myeloid cell; C/EBP-␣ is capable of functionally blocking the PU.1 protein, and this interference is mediated through interaction between the ␤3/␤4 region of the PU.1 DNA-binding domain and the leucine zipper in the DNA-binding domain of C/EBP-␣, which in turn displaces PU.1's co-activator c-Jun
Additionally, a mutual corepression was found between Egr-2/Nab-2, a complex of genes activated by PU.1, and Gfi-1, a gene activated by C/EBP-␣. Because both Egr-2 and Gfi-1 are known to promote the expression of genes specific to macrophages and neutrophils, respectively, their corepression may indeed be the basis of a positive feedback loop that promotes and stabilizes a particular cell fate during CMP differentiation. For instance, when PU. 1 
and C/EBP-␣ are expressed at low levels as is the case in undifferentiated CMPs, positive feedback between Egr-2/Nab-2 and Gfi-1 is sufficiently weak such that neither is amplified and the mixed-lineage stage persists. In contrast, when PU.1 is expressed at a much higher level than C/EBP-␣, the mixed-lineage state of gene expression is resolved and the system is monostable, promoting differentiation of the CMP into a macrophage (or, if the ratio is reversed, into a neutrophil) [105]. C/EBP-␣ also functionally interacts with the activation domain of PU.1, which might disrupt possible protein-protein interactions important for the PU.1-induced differentiation program.
One such candidate is CBP/p300, a co-activator of PU.1 [78] , which binds to the transactivation domain of PU. [110, 111] [112] .
indicates that cooperation between these factors is relevant to the activation of a substantial number of early myeloid genes. In most experiments, the activation seen with C/EBP-␣, c-Myb and PU.1 was equivalent to the multiplication of the individual activations obtained with these factors. This interaction has been termed as 'cooperative' instead of synergistic because synergism exists when a factor combination produces much more than a multiplicative effect
A (Fig. 6) . [78] . (Fig. 7) . causes inactivation of the transcriptional activity of PU.1 by displacing its co-activator c-Jun [114] (Fig. 8) .
91-bp NE promoter region contains three evolutionarily conserved cis elements, which are essential for activation of the promoter in differentiating 32Dcl3 myeloid cells. These elements bound c-Myb (at 249), C/EBP-␣ (at 257) and PU.1 (at 282)
In NIH 3T3 cells, the NE promoter was activated by c-Myb, C/EBP-␣ and PU.1, via their respective binding sites. Cooperative activation was seen by any combination of c-Myb, C/EBP-␣ and PU.1, including all three together, again via their DNA-binding sites. In CV-1 cells, but not in NIH 3T3 cells, cooperation between Myb and C/EBP-␣ depended on the integrity of the PU.1-binding site
AML-1
AML-1 is a member of the CBF or polyoma EBP (PEBP2) family [113]. During monocytic commitment and differentiation, AML-1B regulates the myeloid-specific expression of M-CSF receptor in synergistic association with C/EBP-␣ and PU.1 by forming a ternary complex on DNA [32]
AML-1 and PU.1 interact physically and this interaction occurs
AML [118, 119] (Fig. 9) 
